Search

Displaying results 3931 - 3940 of 10000 in total
  1. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  2. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.

    Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine, (S)-N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine
  3. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

  4. Drug

    Oxacillin

    go.drugbank.com/drugs/DB00713
    ApprovedInvestigational

    An antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.

    International brands: Staficilin-NProducts: OXACILINA 1 G, OXACILINA 1G
  5. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

  6. Drug

    Iodoform

    go.drugbank.com/drugs/DB13813
    ApprovedInvestigationalVet approvedWithdrawn

    Iodoform is soluble in fatty acids and decomposes releasing iodine in nascent state (96,7% of iodine) when in contact with secretions or endodontic infections [A32893]. … Iodoform has also been found in dental paste and root canal filling materials in combination with other intracanal medications due to its radiopacity [A32893].

  7. Drug

    Keyhole limpet hemocyanin

    go.drugbank.com/drugs/DB05299
    ApprovedInvestigationalWithdrawn

    Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins. … Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet.

  8. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    [A191475] It has been in use in Russia for approximately 25 years and in China since 2006. … [A191475] Umifenovir's ability to exert antiviral effects through multiple pathways has resulted in considerable investigation into its use for a variety of enveloped and non-enveloped RNA and DNA viruses

  9. Target

    Cytochrome b

    go.drugbank.com/bio_entities/BE0004428
    TargetPlasmodium falciparum

    Component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex) that is part of the mitochondrial respiratory chain. … The b-c1 complex mediates electron transfer from ubiquinol to cytochrome c. Contributes to the generation of a proton gradient across the mitochondrial membrane that is then used for ATP synthesis.

    Synonyms: Complex III subunit 3, Complex III subunit III
  10. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.